PDCD1 and melanoma: Five-year overall survival (OS) of patients with melanoma exhibiting distant metastasis (stage IV), treated with anti-PD-1 Ab or anti-PD-1 + anti-CTLA-4 Ab, has been reported at 40% and 50%, respectively [9].